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Introduction: Sentinel lymph node (SLN) biopsy using blue dye and radioisotope
often results in the removal of multiple SLNs. We sought to determine whether there is
a point where the surgeon can terminate the procedure without sacrificing accuracy.
Methods: One thousand one hundred ninety-seven patients from University of
Michigan and the Mayo Clinic undergoing SLN biopsy formed the study population.
Surgeons removed all SLNs until counts within the axilla were less than 10% of the
highest node ex vivo and recorded the order in which they were removed.
Results: The mean number of SLNs removed per patient was 2.5 (range 1–9).
Approximately 42% of patients had three or more lymph nodes removed, while 19%
had four or more lymph nodes removed. Eighteen percent of patients (132/725) at
University of Michigan and 22% (103/472) at Mayo Clinic had a positive SLN.
Ninety-eight percent (231/235) of patients with lymph node metastases were identified
by the 3rd SLN while 100% were identified by the 4th SLN.
Conclusion: Among patients undergoing SLN biopsy for breast cancer, the only
positive SLN is rarely identified in the 4th or higher node. Terminating the procedure
at the 4th node may lower the cost of the procedure and reduce morbidity.
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INTRODUCTION
Sentinel lymph node (SLN) biopsy has become a
standard method for staging the axilla in clinically node
negative patients with breast cancer [1,2]. The benefit of
SLN biopsy in providing accurate staging information
while avoiding the morbidity of a complete axillary
lymph node dissection has been well-documented [3–5].
The SLN is defined as the first lymph node to receive
lymphatic drainage from the tumor and is therefore
the most likely lymph node to harbor micrometastases
if they exist. The practical definition of the SLN is
different, however. With the combined use of technetium
99 m-sulfur colloid (99mTc) and blue dye to identify SLN,
multiple lymph nodes are often found containing tracer.
Any lymph node that exhibits radioactivity, is blue or
has a blue afferent lymphatic channel, or is palpably
suspicious is excised and labeled as a SLN [6].
A dual tracer technique with blue dye and radioisotope
increases both the success rate and the accuracy of the
procedure [7–9], but also increases the number of lymph
nodes removed per case [10,11]. The degree of radio-
activity necessary to excise and define a lymph node as
‘sentinel’ varies among surgeons [6,12–14]. Several
authors have demonstrated that the hottest SLN (the
node with the highest counts) is not always the node
to harbor metastasis [10,15–17], and so a threshold for
excising additional SLNs is necessary. What that thresh-
old should be, however, remains in question. With a lower
threshold, the surgeon is less likely to miss a positive
SLN but more likely to remove more lymph nodes per
case. Furthermore, the absolute number of counts in the
node varies depending on factors such as the dose and
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type of radioactive colloid, time interval from injection to
operation, the type of gamma probe, and its calibration.
The purpose of this analysis was to determine whether
there is a threshold (based on number of SLNs removed)
after which the surgeon does not need to excise additional
lymph nodes.
MATERIALS AND METHODS
Medical records were reviewed for 1,197 breast cancer
patients who underwent successful lymphatic mapping
and SLN biopsy between October 1998 and December
2004 at the University of Michigan (n¼ 725) and
from March 2003 to December 2005 at the Mayo Clinic
(n¼ 472). Approval of this study was granted by the
respective Institutional Review Boards. All patients
underwent injection of 99mTc-sulfur colloid (CIS-US,
Inc., Bedford, MA) either peri-tumorally or periareolar;
injection was either the night before or the morning of
the procedure. Isosulfan blue dye (Lymphazurin 1%;
Hirsch Industries, Inc., Richmond, VA) was utilized in
710 patients (except 19 patients who had the procedure
performed during a national shortage) at the University of
Michigan, while methylene blue dye (American Regent,
Inc., Shirley, NY) was used in all the patients at the Mayo
Clinic. Blue dye was injected either peri-tumorally or at
the subareolar location, followed by 3–5 min of massage
to promote lymphatic flow. A handheld gamma probe
(Navigator GPS; US Surgical) was used to identify
transcutaneous hot spots and to guide dissection of the
SLN(s).
Lymph nodes were removed and labeled as SLNs if
they were palpably suspicious, blue, had blue-stained
afferent lymphatic vessels, or were hot, defined as the
hottest node plus any lymph node with at least 10% of the
ex vivo counts per minute (CPM) of the hottest node. The
SLNs were numbered in the order they were excised,
so the first node was not necessarily the hottest node
based on CPM. At the Mayo Clinic, a preliminary
frozen section was performed on all SLNs, while this
was performed selectively at the University of Michigan.
If the SLN was negative for tumor, the node was
measured and cut entirely along its longitudinal axis
into sections of 1.5–2 mm thickness. The sections were
submitted in formalin for paraffin section histology.
At least four additional levels were examined with
hematoxylin and eosin (H&E) and cytokeratin antibody
(AE1/3, monoclonal antibody, 1/250; Boehringer
Mannheim, Indianapolis, IN), together with a negative
control. The routine use of IHC for cytokeratin was
discontinued at the University of Michigan in July 2002.
For the Michigan dataset, sentinel nodes positive by IHC
but negative by H&E were considered negative. In
contrast, IHC was utilized uniformly for all Mayo Clinic
patients. Of 472 patients in the Mayo dataset, information
on IHC staining was recorded for 414 patients. Of these,
five patients had positive SLNs based on IHC alone (all
were N0iþ). IHC was not used on any non-SLNs.
RESULTS
The study group consisted of 1,197 patients; 725 from
the University of Michigan and 472 from the Mayo
Clinic. The median age of the patients was 55 years
(range, 17–85 years) in the Michigan dataset and was
64 years (range, 24–90 years) in the Mayo dataset.
Overall, 71% of patients had invasive ductal carcinoma
and 11% had invasive lobular carcinoma. The patient and
tumor characteristics presented in Table I were similar
between the two institutions.
The mean number of SLNs removed by the surgeon in
both the Michigan (range, 1–9) as well as in the Mayo
dataset (range, 1–8) was 2.5. The number of lymph nodes
surgically removed and pathologically examined at each
institution is shown in Table II. Often, the surgeon
removes and labels a single node as a SLN, but the
pathologist identifies more than one node within the
specimen. Based on pathology reports, the mean number
of SLNs examined per patient was 3.1 (range, 1–24) at
the University of Michigan and 2.8 (range, 1–9) at the
Mayo Clinic. The frequency distribution of the number of
SLNs removed by the surgeon and identified by the
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n % n %
Tumor histology
Invasive ductal 511 70 343 73
Invasive lobular 68 10 55 12
DCIS 55 7 42 9
DCIS with microinvasion 35 5 — —
Other 56 8 32 6
Tumor size
Tis 55 8 42 9
T1mic 35 5 8 2
T1a 76 10.5 25 5
T1b 181 25 91 20
T1c 249 35 193 42
T2 111 15.5 86 18
T3 7 1 18 4
Unknown 11 9
Tumor grade (invasive)
1 144 21.3 104 25
2 283 42.4 226 53
3 127 19.1 87 22
Unknown 116 17.2 13
Estrogen receptor (invasive)
Positive 448 66.8 374 87
Negative 159 23.6 56 13
Unknown 63 —
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pathologist was remarkably similar between the two
institutions. Overall, 42% of patients had three or more
SLNs removed while 19% had four or more lymph
nodes removed. Nearly half of the patients had three or
more and a quarter had four or more nodes examined
histologically.
The position of the first positive node in the order of
SLN removal is presented in Table III. Of the 725 patients
undergoing successful SLN biopsy at the University of
Michigan, 132 (18%) had metastasis to at least one SLN.
There was an average of 1.5 positive SLN per node-
positive patient. Of the 132 patients with lymph node
metastases, 66% (87 patients) were positive in the first
lymph node removed by the surgeon, 86% (114 patients)
by the second node, 98% (130) by the third node, and
100% (132 patients) by the 4th node. There were no cases
where the surgeon needed to excise more than four nodes
to identify metastases.
Of the 472 patients having successful SLN biopsy at the
Mayo Clinic, 103 (22%) had metastasis to at least one SLN
(Table III). Of the 103 patients with SLN metastases, 87%
(90) were positive in the 1st node removed by the surgeon,
95% (98) by the 2nd node, 98% (101) by the 3rd node, and
100% (103) by the 4th node. Similar to the Michigan study
population, there were no cases where the surgeon needed
to excise more than four nodes to identify metastases.
Despite the use of IHC at the Mayo Clinic and the five
additional patients who were positive by IHC only, the
routine use of IHC did not alter these results.
Terminating the procedure after the 3rd node would
have shortened the operation for 133 (18%) at Michigan
and 111 (26%) patients at Mayo, and avoided histological
evaluation of 223 and 137 nodes, respectively, but would
have missed disease in 4 of 235 patients (1.7%). In the
Michigan dataset, terminating the procedure after the
after the 4th node removed would not have missed any
positive cases but overall spared 52 patients (7%) the
extra time in the OR to identify additional nodes and the
histologic evaluation of 90 additional nodes. In the Mayo
dataset, this approach would spare 34 patients from the
additional time in the OR (7% of the total) and the
histologic evaluation of 52 nodes without missing any
positive SLNs (Table IV).
DISCUSSION
Sentinel lymph node biopsy has evolved as the
preferred technique for axillary staging in breast cancer.
Journal of Surgical Oncology DOI 10.1002/jso
TABLE II. Number of SLNs Excised and Examined
No. of SLN/s
Excised by surgeon Examined by pathologist
Michigan dataset Mayo dataset Michigan dataset Mayo dataset
n % n % n % n %
1 168 23 97 22 147 20 91 19
2 261 36 151 34.5 216 30 133 28
3 162 22 99 23 156 22 115 24
4 81 11 51 12 77 11 67 14
5 30 4 21 5 44 6 31 6.5
6 12 1.7 10 2 28 4 21 4
7 6 0.8 1 0.2 11 1.5 9 2
8 2 0.3 2 0.4 15 2 3 0.6
9 2 0.3 — — 8 1 2 0.4
10 — — — — 9 1 — —
11 — — — — 6 0.8 — —
12 — — — — 5 0.7 — —
TABLE III. Order In Which the First Positive SLN was Removed
Michigan dataset Mayo dataset
n % Of cases
Cumulative
frequency (%) n % of Cases
Cumulative
frequency (%)
Node negative 593 82 — 369 78 —
Node positive 132 18 — 103 22 —
1st Node removed 87 66 66 90 87 87
2nd Node removed 27 20 86 8 8 95
3rd Node removed 16 12 98 3 3 98
4th Node removed 2 2 100 2 2 100
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Studies have shown that the SLN can be identified in 96%
of cases with a low false negative rate [18–20]. The mean
number of SLNs removed in the SLN biopsy procedure
ranges from 1.2 to 3.4 per patient, with a total number
ranging from 1 to 8 in the published literature
[11,13,17,18]. Removal of more SLNs increases time in
the OR, time for the pathologist, costs of the procedure,
and axillary morbidity [21]. The ACOSOG Z0010
prospective trial of SLN biopsy in breast cancer reported
significantly higher rates of axillary seroma and wound
infection in patients who had five or more SLNs removed,
compared to those with up to four nodes removed [21]. It
is therefore worthwhile to determine how many SLNs
should be excised to adequately stage the axilla. In
this study we approached this question with a simple
criterion—the number of SLNs removed by the surgeon.
We sought to discover whether there is a numerical
threshold after which the surgeon does not need to excise
additional lymph nodes without sacrificing accuracy.
With excision of all blue, palpably suspicious, and hot
nodes based upon a 10% rule, 19% of patients in our
study had four or more lymph nodes removed, and 28%
had a similar number of SLNs examined pathologically.
Ninety-eight percent of SLN positive patients had
metastasis in the first three SLNs removed, with the
remaining 2% found in the fourth SLN. There were no
cases where the surgeon needed to excise more than four
SLNs to identify SLNmetastases. These data suggest that
it is rare to identify nodal metastasis in the 4th or higher
sentinel node, assuming that all nodes meeting the
definition of a SLN (see Material and Methods) have
been removed.
The optimal techniques for SLN biopsy have been
debated, but there is considerable support for a dual tracer
technique [7–9], using both blue dye and radioisotope
injection. Although a single SLN should in theory
accurately reflect the status of the nodal basin, published
clinical trial results confirm that in practice the false
negative rate is lower with excision of more than one SLN
[22]. When radioisotope is used for lymphatic mapping,
some threshold of radioactivity is selected to define the
number of SLNs removed. Various count ratios have been
used: SLN to background, SLN to non-SLN, or SLN to
hottest SLN. Most surgeons use a ratio of the in vivo
CPM to the background radioactivity or to the ex vivo
node counts compared to that of the node with the highest
CPM [6,10,12–15,23]. A common practice is to remove
all nodes with counts greater than 10% of the hottest
node, based on results from published investigations
[10,23].
Several groups have examined this subject and
found similar results, with all positive nodes identified
by the 4th node (Table V), although there were a few
exceptions. The Axillary Lymphatic Mapping Against
Nodal Axillary Clearance (ALMANAC) Trialists group
reported that 99.6% of node positive patients were
identified within the first four sentinel nodes removed
[23]. McCarter et al. [24] fromMemorial Sloan Kettering
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TABLE IV. Number of Excess SLNs Removed by the Surgeon Beyond the 4th SLN
No. of excess SLNs
Michigan dataset Mayo dataset
No. of patients
No. of excess
nodes removed No. of patients
No. of excess
nodes removed
1 30 30 21 21
2 12 24 10 20
3 6 18 1 3
4 2 8 2 8
5 2 10 — —
Total 52 (7% of total) 90 34 (7% of total) 52
TABLE V. Studies Examining How Many Nodes Needed to be Removed before Identifying All Positive SLN
Author and institution # Pos SLN 1st Node (%) 2nd Node (%) 3rd Node (%) 4th Node (%) 5th Node (%) 6th–8th Node (%)
MDACC/Duke [29] 278 (11%) 79 96 99 100 N/A N/A
University of Michigan 132 (18%) 66 86 98 100 N/A N/A
Mayo Clinic 103 (22%) 87 95 98 100 N/A N/A
Beaumont Hospital [25] 172 (24%) 76.6 91 97 98.8 99.4 100
Ludwig Boltzmann [30] 105 (40%) 91.4 99 100 N/A N/A N/A
Virginia Mason [31] 129 (24%) 65 98.4 99.2 100 N/A N/A
MSKCC [24] 241 (15%) 75.3 92.9 98 99.1 99.6 100
Wagga Wagga [32] 33 (29%) 88 97 100 N/A N/A N/A
University South Florida [33] 128 (27%) 89 98.4 99.2 100 N/A N/A
Ohio State University [34] 104 (29%) 83 97 98 99 100 N/A
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Cancer Center, reported that 99.1% of patients with a
positive SLN were found by the fourth SLN removed,
and 99.6% were found in the first five nodes removed.
Woznick et al. [25] from Beaumont hospital evaluated
172 patients with positive SLN and found that 100%
of positive nodes were found by six nodes removed.
Chagpar et al. [26] reviewed data from the Louisvile
Breast Sentinel Lymph Node Study and found that 100%
of disease was not identified until >10 nodes were
removed, although after 4 nodes were removed, 98.5% of
positive SLN were identified. Even in these reports where
four nodes did not identify 100% of disease, very few
patients (<2%) would have been adversely affected by
terminating the procedure at the 4th node. Mathematical
models of the impact of a false-negative SLN biopsy on
10-year breast cancer mortality demonstrate an almost
negligible impact with 1–2% changes in the false
negative rate [27].
Sentinel lymph node biopsy has an inherent false
negative rate in the range of 4–10% [18–20]. Based upon
the findings of this study and the others summarized
above, terminating the SLN biopsy procedure at four
nodes should identify a positive SLN in almost all
cases and thus increase the false negative rate by less than
1%. Attempts have been made by various researchers to
define optimal surgeon experience for reducing false
negative rate associated with SLN biopsy. Anywhere
between 5 [18] and 20 procedures have been used as
the cut-off point [28]. However, most of the validation
studies for SLN biopsy technique are from the late 1990s
and did not take surgeon’s experience into account. Data
from pre-randomization surgical training for the NSABP
B-32 trial suggests that adherence to a standardized
protocol of SLN biopsy procedure can lead to technical
success rates of 96% among surgeons with a wide range
of expertise for this procedure [18]. Based on these points
it seems reasonable to presume that terminating the SLN
biopsy procedure at four nodes should have minimal
incremental impact on the false negative rate of SLN
biopsy procedure, as long as it is performed after
completion of recommended training in the procedure.
Some surgeons do advocate continuing the SLN biopsy
procedure until all hot nodes are removed. However, there
is a cost to this approach. Although it may seem callous to
examine the costs of breast cancer care, the cost of health
care in the United States is a significant problem. Even
though the number of excess SLNs removed and examined
per patient is small, given the additional time spent in the
OR and time for the pathologist to thin-section each
node, the cumulative effect of this practice on health
care resources is substantial. A challenge to surgeons is to
reduce unnecessary costs without compromising patient
care; thus, physicians should bear in mind the costs of
new technologies and treatments in cancer care. While it is
desirable to pursue the highest level of accuracy with the
SLN biopsy procedure, the relative gains in accuracy from
excision of multiple nodes may not be justified by the
attendant increased cost and morbidity. In a procedure
with a known false negative rate of approximately 7%,
removing more than four SLNs will contribute little to
improved accuracy, based on the available data.
In summary, our findings and other published literature
support the conclusion that a positive sentinel node will
be identified in 100% of cases within the first four
sentinel nodes removed by the surgeon, according to
current practices. Terminating the SLN biopsy procedure
at four lymph nodes will have no impact on the false
negative rate, but there is a cost savings associated
with setting such a threshold. As long as the surgeon is
confident that the blue and hottest node(s) have been
removed, it is reasonable to limit sentinel node removal to
four nodes in order to reduce both the cost as well as the
morbidity of the procedure.
REFERENCES
1. Veronesi U, Paganelli G, Viale G, et al.: A randomized
comparison of sentinel node biopsy with routine axillary
dissection in breast cancer. N Engl J Med 2003;349:546–553.
2. Giuliano AE, Dale PS, Turner RR, et al.: Improved staging of
breast cancer with sentinel lymphadenectomy. Ann Surg 1995;3:
394–401.
3. Blanchard DK, Donohue JH, Reynolds C, et al.: Relapse and
morbidity in patients undergoing sentinel lymph node biopsy
alone or with axillary dissection for breast cancer. Arch Surg
2003;138:482–488.
4. Ivens D, Hoe AL, Podd TJ, et al.: Assessment of morbidity from
complete axillary dissection. Br J Cancer 1992;66:136–138.
5. Sener SF, Winchester DJ, Martz CH: Lymphedema after sentinel
lymphadenectomy for breast carcinoma. Cancer 2001;92:748–
752.
6. Morton DL, Bostick PJ: Will the true sentinel node please stand?
Ann Surg Oncol 1999;6:12–14.
7. Degnim AC, Oh K, Cimmino VM, et al.: Is blue dye indicated
for sentinel lymph node biopsy in breast cancer patients with
a positive lymphoscintigram? Ann Surg Oncol 2005;12:712–
717.
8. McMasters KM, Tuttle TM, Carlson DJ, et al.: Sentinel lymph
node biopsy for breast cancer: A suitable alternative to routine
axillary dissection in multi-institutional practice when optimal
technique is used. J Clin Oncol 2000;18:2560–2566.
9. Cody HS, Fey J, Akhurst T, et al.: Complementarity of blue dye
and isotope in sentinel node localization for breast cancer:
Univariate and multivariate analysis of 966 procedures. Ann Surg
Oncol 2001;8:13–19.
10. Martin RCG, Edwards MJ, Wong SL, et al.: Practical guidelines
for optimal gamma probe detection of sentinel lymph nodes in
breast cancer: Results of a multi-institutional study. Surgery 2000;
128:139–144.
11. Borgstein PJ, Pijpers R, Comans EF, et al.: Sentinel lymph node
biopsy in breast cancer: Guidelines and pitfalls of lymphoscintig-
raphy and gamma probe detection. J Am Coll Surg 1998;186:
275–283.
12. Albertini JJ, Lyman GH, Cox C, et al.: Lymphatic mapping and
sentinel node biopsy in the patient with breast cancer. JAMA
1996;276:1818–1822.
13. Krag D, Weaver D, Ashikaga T, et al.: The sentinel node in breast
cancer: A multicenter validation study. N Engl J Med 1998;339:
941–946.
Journal of Surgical Oncology DOI 10.1002/jso
558 Zakaria et al.
14. Nathanson SD: Will the true sentinel node please stand? (Letter).
Ann Surg Oncol 1999;6:514–516.
15. Camp ER, Cendan JC, Feezor R, et al.: The hottest sentinel lymph
node is not always the positive node. Am Surg 2004;70:475–478.
16. Bourgeois P, Nogaret JM, Veys I, et al.: How ‘‘hot’’ is the
pathologically positive sentinel lymph node in breast cancer
patients? Nucl Med Commun 2003;24:513–518.
17. Tafra L, Lannin DR, Swanson MS, et al.: Multicenter trial of
sentinel node biopsy for breast cancer using both technetium
sulfur colloid and isosulfan blue dye. Ann Surg 2001;233:51–59.
18. Harlow SP, Krag DN, Julian TB, et al.: Prerandomization surgical
training for the NSABP-B32 trial—a randomization phase III
clinical trial to compare sentinel node resection to conventional
axillary dissection in clinically node negative breast cancer. Ann
Surg 2005;241:48–54.
19. Veronesi U, Paganelli G, Galimberti V, et al.: Sentinel node
biopsy to avoid axillary dissection in breast cancer with clinically
negative lymph nodes. Lancet 1997;349:1864–1867.
20. Giuliano AE, Jones RC, Brennan M, et al.: Sentinel lymphade-
nectomy in breast cancer. J Clin Oncol 1997;15:2345–2350.
21. Wilke LG, McCall LM, Posther KE, et al.: Surgical complications
associated with sentinel lymph node biopsy: Results from a
prospective international cooperative group trial. Ann Surg Oncol
2006;13:491–500.
22. Wong SL, Edwards MJ, Chao C, et al.: Sentinel lymph node
biopsy for breast cancer; impact of the number of sentinel nodes
removed on the false-negative rate. J Am Coll Surg 2001;192:
684–689.
23. Goyal A, Newcombe RG, Chhabra A, et al.: Factors affecting
failed localization and false-negative rates of sentinel node biopsy
in breast cancer-results of the ALMANAC validation phase.
Breast Cancer Res Treat 2006;99:203–208.
24. McCarter MD, Yeung H, Fey J, et al.: The breast cancer patient
with multiple sentinel nodes: When to stop? JAm Coll Surg 2001;
192:692–697.
25. Woznick A, Franco M, Bendick P, Benitez PR: Sentinel lymph
node dissection for breast cancer: How many nodes are enough
and which technique is optimal? Am J Surg 2006;191:330–
333.
26. Chagpar AB, Scoggins CR, Martin RCG II, et al.: Are 3 sentinel
nodes sufficient? Arch Surg 2007;142:456–460.
27. Vaidya JS, Dewar JA, Brown DC, et al.: A mathematical model
for the effect of a false-negative sentinel node biopsy on breast
cancer mortality: A tool for everyday use. Breast Cancer Res
2005;7:225–227.
28. McMasters KM, Wong SL, Chao C, et al.: Defining the optimal
surgeon experience for breast cancer sentinel lymph node biopsy:
A model for implementation of new surgical techniques. Ann
Surg 2001;234:292–300.
29. Grubbs E, Bennett K, Westlund R, et al.: Sentinel lymph node
biopsy in breast cancer: How many nodes need to be removed
(abstract). Ann Surg Oncol 2007;14 41.
30. Schrenk P, Rehberger W, Shamiyeh A, et al.: Sentinel node biopsy
for breast cancer: Does the number of sentinel nodes removed
have an impact on the accuracy of finding a positive node? J Surg
Oncol 2002;80:130–136.
31. Duncan M, Cech A, Wechter D, et al.: Criterial for establishing
the adequacy of a sentinel lymphadenectomy. Am J Surg 2004;
187:639–642.
32. Low KS, Littlejohn DR: Optimal number of sentinel nodes after
intradermal injection isotope and blue dye. ANZ J Surg 2006;76:
472–475.
33. Zervos EE, Badgwell BD, Abdessalam SF, et al.: Selective
analysis of the sentinel node in breast cancer. Am J Surg 2001;
182:372–376.
34. Povoski SP, Young DC, Walker MJ, et al.: Re-emphasizing
the concept of adequacy of intraoperative assessment of
the axillary sentinel lymph nodes for identifying nodal
positivity during breast cancer surgery. World J Surg Oncol
2007;5:18.
Journal of Surgical Oncology DOI 10.1002/jso
SLN Biopsy for Breast Cancer 559
